NEW YORK (GenomeWeb News) – Cancer diagnostics firm DiagnoCure said on Friday that revenues for the first quarter of its fiscal year 2014 decreased 12 percent year over year.

DiagnoCure's revenues are derived completely from royalties from the sale of the Progensa PCA3 assay for prostate cancer, marketed by Hologic, and the Quebec City-based company attributed the year-over-year revenue drop on Hologic's failure to promote and market the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.